Y-mAbs Therapeutics, Inc.

NasdaqGS:YMAB Stok Raporu

Piyasa değeri: US$657.0m

Y-mAbs Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Y-mAbs Therapeutics has been growing earnings at an average annual rate of 14.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 51.5% per year.

Anahtar bilgiler

14.8%

Kazanç büyüme oranı

19.5%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı51.5%
Özkaynak getirisi-25.8%
Net Marj-28.4%
Sonraki Kazanç Güncellemesi08 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers

Oct 21

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%

Sep 12
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%

Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)

Aug 12

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Jul 15
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Jun 02
Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Y-mAbs: There's A Ceiling Here Somewhere

May 09

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Mar 14
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Feb 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Y-mAbs Therapeutics: A Monoclonal Antibody Play

Jan 14

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

Nov 13
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Jul 16
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

May 13
Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Apr 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Mar 22
Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Dec 13
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Aug 13
Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers

Jul 12

Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers

May 30

Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

May 12
Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

Gelir ve Gider Dağılımı

Y-mAbs Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqGS:YMAB Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 2487-255154
31 Mar 2484-224553
31 Dec 2385-214550
30 Sep 2393-194456
30 Jun 2385-394862
31 Mar 2375-745076
31 Dec 2265-965289
30 Sep 2243-1345798
30 Jun 2240-1355799
31 Mar 2240-1175892
31 Dec 2135-555791
30 Sep 2146-385686
30 Jun 2137-425484
31 Mar 2126-605095
31 Dec 2021-1194693
30 Sep 200-1233886
30 Jun 200-1143185
31 Mar 200-912469
31 Dec 190-812063
30 Sep 190-721657
30 Jun 190-591447
31 Mar 190-521240
31 Dec 180-43934
30 Sep 180-38930
30 Jun 180-31724
31 Mar 180-24518
31 Dec 170-19514

Kaliteli Kazançlar: YMAB is currently unprofitable.

Büyüyen Kar Marjı: YMAB is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: YMAB is unprofitable, but has reduced losses over the past 5 years at a rate of 14.8% per year.

Büyüme Hızlandırma: Unable to compare YMAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: YMAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Özkaynak Getirisi

Yüksek ROE: YMAB has a negative Return on Equity (-25.82%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin